Background {#Sec1}
==========

Hepatocellular carcinoma (HCC) is one of the leading causes of death all over the world \[[@CR1], [@CR2]\]. Although we still did not reveal the exact mechanism of its pathogenesis, it was evident that genetic components were essential in the development of HCC. Firstly, the incidences of HCC in different populations were quite different \[[@CR3], [@CR4]\], and genetic background was probably one of the reasons behind differences in disease prevalence across different populations. Secondly, numerous susceptible genetic loci of HCC were also identified and validated by existing genetic association studies \[[@CR5], [@CR6]\].

Mannose-binding lectin (MBL) and interleukin-18 (IL-18) are crucial modulators of immunological reactions, whereas vitamin D receptor (VDR) and vascular endothelial growth factor (VEGF) are vital for both immune-regulation and angiogenesis \[[@CR7]--[@CR10]\]. So, if a genetic polymorphism could alter the transcription activity of *VDR/VEGF/IL-18/MBL* or the protein structure of VDR/VEGF/IL-18/MBL, there is a possibility that this polymorphism may lead to the development of chronic inflammatory cellular injuries and also confer susceptibility to many types of malignancy including HCC.

In the past 20 years, many studies explored associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC, yet the conclusions of these studies were somehow inconsistent \[[@CR11]--[@CR40]\]. To better clarify associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC, we designed this study to get a more credible conclusion by combing the results of all relevant studies.

Methods {#Sec2}
=======

We wrote this meta-analysis in accordance with the requirements of the PRISMA guideline \[[@CR41]\].

Literature search and inclusion criteria {#Sec3}
----------------------------------------

To retrieve eligible articles, we searched PubMed, WOS, Embase, and CNKI with keywords listed below: ("vitamin D receptor" or "VDR" or "vascular endothelial growth factor" or "VEGF" or "interleukin 18" or "IL 18" or "mannose-binding lectin" or "Mannose-binding protein" or "MBL" or "MBP") and ("polymorphism" or "variant" or "variation" or "mutation" or "SNP" or "genome-wide association study" or "genetic association study" or "genotype" or "allele") and ("hepatocellular carcinoma" or "HCC"). The references of retrieved articles were also screened by us to identify other potentially relevant articles.

To be included in this meta-analysis, some criteria must be met: (I) about associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC in humans; (II) Offer genotypic distribution of *VDR/VEGF/IL-18/MBL* polymorphisms in patients with HCC and controls; (III) full manuscript in English or Chinese is retrievable. Publications were deemed to be ineligible for inclusion if (I) not about polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC; (II) narrative reviews, systematic reviews, or comments; (III) studies only involved HCC patients. We only included the most up to date study for analyses if duplicate publications were found during the literature search.

Data extraction and quality assessment {#Sec4}
--------------------------------------

Two authors extracted the following essential information from eligible studies: (I) name of the leading author; (II) published year; (III) country of the leading author; (IV) ethnicity of involved participants; (V) number of patients with HCC and controls in each study; (VI) genotype distributions of polymorphisms in *VDR/VEGF/IL-18/MBL* among patients with HCC and controls. *P* values of Hardy-Weinberg equilibrium (HWE) were also calculated.

The authors used the Newcastle-Ottawa scale (NOS) to assess the quality of eligible publications \[[@CR42]\]. The score range of NOS is between 0 and 9, when a study got a score of 7 or more, we considered that the methodology quality of this study was good

Two authors extracted data and assessed the quality of eligible studies. The authors wrote to the leadings authors for additional information if essential information was found to be incomplete.

Statistical analyses {#Sec5}
--------------------

We used Review Manager to combine the results of individual studies. *Z* test was employed to assess associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and susceptibility to HCC. The statistical significance threshold of *P* value was set at 0.05. We used *I*^2^ statistics to assess between-study heterogeneities. We used Random-effect models (DerSimonian-Laird method) to combine the results if *I*^2^ is larger than 50%. Otherwise, fixed-effect models (Mantel-Haenszel method) were used to combine the results \[[@CR43], [@CR44]\]. We further carried out subgroup analyses by ethnicity to get ethnic-specific results. We examined the stability of combined results by deleting one study each time and combining the results of the remaining studies. We used funnel plots to estimate whether our combined results may be influenced by publication biases.

Results {#Sec6}
=======

Characteristics of included studies {#Sec7}
-----------------------------------

We found 168 articles during literature searching. Forty-five articles were assessed for eligibility after excluding unrelated or duplicate articles. We further excluded eight reviews and six case series, and another one publication was excluded because of missing crucial data. Totally, 30 articles were ultimately found to be eligible for inclusion (Fig. [1](#Fig1){ref-type="fig"}). Extracted data of eligible articles were summarized in Table [1](#Tab1){ref-type="table"}. Fig. 1.Flowchart of study selection for the present study Table 1The characteristics of included studies for this meta-analysisFirst author, yearCountryEthnicityType of diseaseMedical history of patientsSample size\
Case/controlGenotype distribution\
(wtwt/wtmt/mtmt)*P* value for HWENOS scoreCases controlsVDR rs7975232 Barooah 2019 \[[@CR11]\]IndiaSouth AsianHCCNA60/10249/11/059/35/80.3918 Falleti 2010 \[[@CR12]\]ItalyCaucasianHCCViral hepatitis 87%80/16027/38/1553/85/220.1898 Hung 2014 \[[@CR13]\]TaiwanEast AsianHCCNA92/10065/24/355/40/50.5058 Yao 2013 \[[@CR16]\]ChinaEast AsianHCCHBV 100%, alcohol intake 34.9%436/532112/216/108114/275/1430.3958VDR rs1544410 Barooah 2019 \[[@CR11]\]IndiaSouth AsianHCCNA60/10252/8/080/16/6\< 0.0018 Falleti 2010 \[[@CR12]\]ItalyCaucasianHCCViral hepatitis 87%80/16033/35/1245/87/280.2068 Hung 2014 \[[@CR13]\]TaiwanEast AsianHCCNA92/10085/7/089/11/00.5608 Yao 2013 \[[@CR16]\]ChinaEast AsianHCCHBV 100%, alcohol intake 34.9%436/532112/217/107142/259/1310.5508VDR rs2228570 Falleti 2010 \[[@CR12]\]ItalyCaucasianHCCViral hepatitis 87%80/16036/36/869/73/180.8438 Liu 2015 \[[@CR14]\]ChinaEast AsianHCCNA105/10041/44/2023/48/290.7158 Peng 2014 \[[@CR15]\]ChinaEast AsianHCCHBV 100%, alcohol intake 90.2%184/29654/90/4077/152/670.6288 Yao 2013 \[[@CR16]\]ChinaEast AsianHCCHBV 100%, alcohol intake 34.9%436/532131/198/107102/241/1890.1118VDR rs731236 Barooah 2019 \[[@CR11]\]IndiaSouth AsianHCCNA60/10248/8/471/21/10\<0.0018 Falleti 2010 \[[@CR12]\]ItalyCaucasianHCCViral hepatitis 87%80/16032/38/1044/88/280.1608 Hung 2014 \[[@CR13]\]TaiwanEast AsianHCCNA92/10086/6/086/14/00.4528 Yao 2013 \[[@CR16]\]ChinaEast AsianHCCHBV 100%, alcohol intake 34.9%436/532115/212/109137/252/1430.2268VEGF rs699947 Liu 2017 \[[@CR19]\]ChinaEast AsianHCCHBV 60.2%, alcohol intake 60.8%476/526301/157/18290/202/340.8828 Machado 2014 \[[@CR20]\]PortugalCaucasianHCCAlcohol intake 100%26/1017/14/519/49/330.9147 Ratnasari 2017 \[[@CR22]\]IndonesiaEast AsianHCCHBV58%, HCV 11%44/5918/21/523/30/60.4027 Wu 2009 \[[@CR23]\]ChinaEast AsianHCCNA92/9048/40/458/28/40.7928 Wu 2013 \[[@CR24]\]ChinaEast AsianHCCHBV48.5%101/11079/21/191/17/20.2718VEGF rs1570360 Baitello 2016 \[[@CR17]\]CanadaMixedHCCHBV 50%, HCV 21%, alcohol intake 56%102/12761/35/673/47/70.8758 Wu 2009 \[[@CR23]\]ChinaEast AsianHCCNA90/9966/24/072/27/00.1168 Wu 2013 \[[@CR24]\]ChinaEast AsianHCCHBV48.5%101/11083/17/175/31/40.7238VEGF rs2010963 Liu 2017 \[[@CR19]\]ChinaEast AsianHCCHBV 60.2%, alcohol intake 60.8%476/526162/232/82200/248/780.9378 Ratnasari 2016 \[[@CR21]\]IndonesiaEast AsianHCCHBV56.5%, HCV 10.8%46/13616/29/126/105/5\<0.0017 Wu 2009 \[[@CR23]\]ChinaEast AsianHCCNA92/9934/40/1834/52/130.3208 Wu 2013 \[[@CR24]\]ChinaEast AsianHCCHBV48.5%101/11028/52/2135/51/240.5068VEGF rs3025039 Baitello 2016 \[[@CR17]\]CanadaMixedHCCHBV 50%, HCV 21%, alcohol intake 56%102/12772/30/090/37/00.0558 Giacalone 2011 \[[@CR18]\]ItalyCaucasianHCCNA96/16281/14/1120/38/40.6368 Liu 2017 \[[@CR19]\]ChinaEast AsianHCCHBV 60.2%, alcohol intake 60.8%476/526359/112/5370/140/160.5368 Wu 2009 \[[@CR23]\]ChinaEast AsianHCCNA92/9963/26/368/30/10.2398 Yvamoto 2015 \[[@CR25]\]BrazilMixedHCCAlcohol intake 47.1%228/56164/64/043/13/00.3267IL-18 rs187238 Bakr 2018 \[[@CR26]\]EgyptSouth AsianHCCHCV 100%90/9066/22/233/65/1\<0.0018 Bao 2015 \[[@CR27]\]ChinaEast AsianHCCHBV 100%153/165122/28/3106/54/50.5488 Chen 2012 \[[@CR28]\]ChinaEast AsianHCCNA228/300159/59/10173/115/120.1837 Dai 2017 \[[@CR29]\]ChinaEast AsianHCCHBV 100%, alcohol intake 42%245/250187/49/9183/65/20.1428 Karra 2015 \[[@CR30]\]IndiaSouth AsianHCCHBV 100%271/280123/134/14159/108/130.3207 Kim 2009 \[[@CR31]\]KoreaEast AsianHCCHBV 100%56/55837/17/2434/122/20.0317 Lau 2016 \[[@CR32]\]TaiwanEast AsianHCCAlcohol intake 63.5%342/559266/73/3476/78/50.3708 Migita 2009 \[[@CR33]\]JapanEast AsianHCCHBV 100%47/6343/3/152/10/10.5317 Teixeira 2009 \[[@CR34]\]BrazilMixedHCCViral hepatitis 67.8%, alcohol intake 63.4%112/20257/48/7100/84/180.9527 Zhang 2016 \[[@CR35]\]ChinaEast AsianHCCHBV 100%109/12782/25/299/24/40.1108IL18 rs1946518 Bakr 2018 \[[@CR26]\]EgyptSouth AsianHCCHCV 100%90/9913/34/4317/45/370.6038 Bao 2015 \[[@CR27]\]ChinaEast AsianHCCHBV 100%153/16537/73/4341/76/480.3228 Chen 2012 \[[@CR28]\]ChinaEast AsianHCCNA228/30047/126/5583/156/610.4297 Dai 2017 \[[@CR29]\]ChinaEast AsianHCCHBV 100%, alcohol intake 42%247/25062/118/6764/124/620.9008 Karra 2015 \[[@CR30]\]IndiaSouth AsianHCCHBV 100%271/28070/152/49102/144/340.1197 Lau 2016 \[[@CR32]\]TaiwanEast AsianHCCAlcohol intake 63.5%342/55988/167/87148/276/1350.7778 Migita 2009 \[[@CR33]\]JapanEast AsianHCCHBV 100%47/6313/26/820/30/130.7777 Teixeira 2009 \[[@CR34]\]BrazilMixedHCCViral hepatitis 67.8%, alcohol intake 63.4%112/20238/56/1885/105/120.2027 Zhang 2016 \[[@CR35]\]ChinaEast AsianHCCHBV 100%109/12722/55/3238/66/230.1278MBL rs7096206 Eurich 2011 \[[@CR36]\]GermanyCaucasianHCCNA62/11527/34/176/37/20.2927 Gu 2016 \[[@CR37]\]ChinaEast AsianHCCNA334/171232/95/7131/33/70.0158 Lin 2015 \[[@CR38]\]ChinaEast AsianHCCAlcohol intake 77.7%220/220125/86/9153/65/20.0828 Su 2016 \[[@CR40]\]ChinaEast AsianHCCHBV 70.2%315/315207/91/17239/72/40.5838MBL rs1800450NA Gu 2016 \[[@CR37]\]ChinaEast AsianHCCNA334/171234/89/11104/59/80.9208 Segat 2008 \[[@CR39]\]ItalyCaucasianHCCNA215/164127/78/10102/49/130.0507 Su 2016 \[[@CR40]\]ChinaEast AsianHCCHBV 70.2%308/315208/88/20239/69/70.4508Abbreviations: *HWE* Hardy-Weinberg equilibrium, *NOS* Newcastle-Ottawa scale, *NA* not available, *HBV* hepatitis B virus infection, *HCV* hepatitis C virus infection

Meta-analyses results for polymorphisms in VDR and HCC {#Sec8}
------------------------------------------------------

Six studies were eligible for estimation of associations between polymorphisms in *VDR* and HCC. *VDR* rs7975232 (dominant comparison OR = 1.58, 95% CI 1.04--2.39; over-dominant comparison OR = 0.80, 95% CI 0.65--0.98) and rs2228570 (dominant comparison OR = 1.54, 95% CI 1.25--1.89; recessive comparison OR = 0.67, 95 % CI 0.54--0.84; allele comparison OR = 1.34, 95% CI 1.06--1.68) polymorphisms were found to be significantly associated with HCC in overall combined analyses. Subgroup analyses showed similar positive findings for rs7975232 (dominant comparison) and rs2228570 (dominant, recessive, and allele comparisons) polymorphisms in East Asians (see Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Supplementary Figure S1). Table 2Meta-analyses results of the current studyVariablesSample sizeDominant comparisonRecessive comparisonOver-dominant comparisonAllele comparison*P* value OR (95%CI) *I*^2^ statistic*P* valueOR (95%CI) *I*^*2*^ statistic*P* value OR (95% CI) *I*^2^ statistic*P* valueOR (95%CI) *I*^2^ statistic*VDR* rs7975232 Overall668/894*0.03*60%*1.58 (1.04--2.39)*0.4231%0.90 (0.69--1.17)*0.03*44%*0.80 (0.65--0.98)*0.0976%1.41 (0.94--2.12) East Asian528/632*0.02*40%*1.39 (1.06--1.81)*0.400%0.88 (0.67--1.17)0.2862%0.75 (0.45--1.26)0.1755%1.30 (0.89--1.89)VDR rs1544410 Overall668/8940.2644%1.15 (0.90--1.45)0.628%0.93 (0.71--1.22)0.540%0.93 (0.75--1.16)0.3050%1.09 (0.93--1.27) East Asian528/6320.980%1.00 (0.74--1.34)0.910%0.98 (0.75--1.30)0.900%1.02 (0.79--1.30)0.960%1.00 (0.83--1.19)VDR rs2228570 Overall805/1088*\< 0.0001*46%*1.54 (1.25--1.89)0.0004*19%*0.67 (0.54--0.84)*0.580%0.95 (0.79--1.14)*0.01*59%*1.34 (1.06--1.68)* East Asian725/928*\< 0.0001*45%*1.63 (1.31--2.04)0.0003*40%*0.66 (0.53--0.83)*0.580%0.95 (0.78--1.15)*0.01*65%*1.40 (1.08--1.82)*VDR rs731236 Overall668/8940.0643%1.25 (0.99--1.58)0.260%0.86 (0.66--1.12)0.4238%0.92 (0.74--1.14)0.0642%1.16 (0.99--1.36) East Asian528/6320.4457%1.34 (0.64--2.82)0.510%0.91 (0.68--1.21)0.5466%0.77 (0.33--1.78)0.3955%1.08 (0.91--1.29)VEGF rs699947 Overall739/8860.9254%1.02 (0.69--1.52)*0.04*0%*0.63 (0.41--0.98)*0.6145%0.95 (0.77--1.17)0.6151%1.08 (0.80--1.46) East Asian713/7850.8464%1.05 (0.66--1.66)0.100%0.67 (0.41--1.08)0.7056%1.08 (0.72--1.65)0.9959%1.00 (0.70--1.42)VEGF rs1570360 Overall293/3360.1237%1.31 (0.93--1.85)0.5719%0.75 (0.29--1.98)0.177%0.78 (0.55--1.11)0.1349%1.26 (0.94--1.70) East Asian191/2090.2860%1.49 (0.72--3.06)0.240%0.27 (0.03--2.41)0.1544%0.71 (0.45--1.13)0.2864%1.46 (0.73--2.91)VEGF rs2010963 Overall715/8710.7955%1.05 (0.72--1.54)0.260%1.17 (0.89--1.55)0.8048%0.97 (0.80--1.19)0.3213%0.93 (0.81--1.07) East Asian715/8710.7955%1.05 (0.72--1.54)0.260%1.17 (0.89--1.55)0.8048%0.97 (0.80--1.19)0.3213%0.93 (0.81--1.07)VEGF rs3025039 Overall994/9700.0812%1.20 (0.98--1.48)0.0838%0.50 (0.23--1.09)0.210%0.87 (0.71--1.08)*0.05*28%*1.21 (1.00--1.46)* East Asian568/6250.100%1.24 (0.96--1.59)0.8769%0.83 (0.09--7.41)0.250%0.86 (0.66--1.11)0.0634%1.24 (0.99--1.56)IL-18 rs187238 Overall1653/25940.3885%1.19 (0.81--1.77)0.5016%1.14 (0.78--1.66)0.2688%0.77 (0.49--1.21)0.5678%1.09 (0.82--1.43) East Asian1180/20220.6281%1.11 (0.73--1.70)0.2733%1.33 (0.80--2.22)0.4981%0.86 (0.55--1.34)0.7678%1.06 (0.74--1.50) South Asian361/3700.6097%1.70 (0.24--12.29)0.650%1.19 (0.57--2.47)0.5398%0.45 (0.04--5.35)0.6992%1.25 (0.42--3.66) HBV881/14430.9078%1.03 (0.65--1.63)0.2343%1.38 (0.81--2.33)0.7378%0.92 (0.57--1.48)0.9674%1.01 (0.70--1.46)IL18 rs1946518 Overall1599/2045*0.002*0%*0.79 (0.68--0.92)0.004*30%*1.26 (1.08--1.48)*0.750%1.02 (0.90--1.17)*0.002*59%*0.78 (0.67--0.91)* East Asian1126/14640.090%0.86 (0.71--1.02)0.150%1.14 (0.95--1.37)0.790%1.02 (0.87--1.19)*0.04*68%*0.80 (0.65--0.99)* South Asian589/679*0.001*0%*0.66 (0.51--0.85)0.02*0%*1.57 (1.09--2.27)*0.9854%0.99 (0.61--1.61)*0.002*0%*0.72 (0.59--0.89)* HBV827/885*0.01*9%*0.77 (0.62--0.95*0.0621%1.25 (0.99--1.57)0.520%1.06 (0.88--1.29)*0.03*73%*0.73 (0.55--0.96)*MBL rs7096206 Overall931/821*\< 0.0001 0.59 (0.48--0.73)* 0%0.3770%1.81 (0.50--6.59)*\< 0.0001*0%*1.59 (1.28--1.97)\< 0.0001* 0%*0.63 (0.53--0.76)* East Asian869/706*\< 0.0001*0%*0.62 (0.50--0.78)*0.3579%2.08 (0.44--9.80)*0.0005*0%*1.50 (1.19--1.88)\< 0.0001* 4%*0.65 (0.53--0.79)*MBL rs1800450 Overall857/6500.8579%0.95 (0.58--1.55)0.9177%1.06 (0.37--3.06)0.7075%1.10 (0.69--1.74)0.9580%0.99 (0.65--1.50) East Asian642/4860.9990%0.99 (0.44--2.23)0.6181%1.47 (0.34--6.30)0.9986%1.00 (0.49--2.03)0.9590%0.98 (0.48--1.99)Abbreviations: *OR* odds ratio, *CI* confidence interval, *NA* not available, *HBV* hepatitis B virus infectionThe values in italics represent that there is statistically significant differences between cases and controls

Meta-analyses results for polymorphisms in VEGF and HCC {#Sec9}
-------------------------------------------------------

Nine studies were eligible for the estimation of associations between polymorphisms in *VEGF* and HCC. *VEGF* rs699947 (recessive comparison OR = 0.63, 95% CI 0.41--0.98) and rs3025039 (allele comparison OR = 1.21, 95% CI 1.00--1.46) polymorphisms were found to be significantly associated with HCC in overall combined analyses. Nevertheless, we did not observe any positive associations in subgroup analyses (see Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Supplementary Figure S1).

Meta-analyses results for polymorphisms in IL-18 and HCC {#Sec10}
--------------------------------------------------------

Ten studies were eligible for the estimation of associations between polymorphisms in *IL-18* and HCC. *IL-18* rs1946518 (dominant comparison OR = 0.79, 95% CI 0.68--0.92; recessive comparison OR = 1.26, 95 % CI 1.08--1.48; allele comparison OR = 0.78, 95% CI 0.67--0.91) polymorphism was found to be significantly associated with HCC in overall combined analyses. Subgroup analyses showed similar positive findings for rs1946518 polymorphism in East Asians (allele comparison), South Asians (dominant, recessive, and allele comparisons), and those with hepatitis B virus (HBV) infection (dominant and allele comparisons) (see Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Supplementary Figure S1).

Meta-analyses results for polymorphisms in MBL and HCC {#Sec11}
------------------------------------------------------

Five studies were eligible for the estimation of associations between polymorphisms in *MBL* and HCC. *MBL* rs7096206 (dominant comparison OR = 0.59, 95% CI 0.48--0.73; over-dominant comparison OR = 1.59, 95% CI 1.28--1.97; allele comparison: OR = 0.63, 95% CI 00.53--0.76) polymorphism was found to be significantly associated with HCC in overall combined analyses. Subgroup analyses showed similar positive findings for rs7096206 polymorphism in East Asians (dominant, over-dominant, and allele comparisons) (see Table [2](#Tab2){ref-type="table"} and Additional file [1](#MOESM1){ref-type="media"}: Supplementary Figure S1).

Sensitivity analyses {#Sec12}
--------------------

We examined the stability of combined results by deleting one study each time and combining the results of the remaining studies. The trends of associations remained consistent in sensitivity analyses, which indicated that the combined results were statistically stable.

Publication biases {#Sec13}
------------------

Funnels plots were employed to estimate whether our combined results may be influenced by publication biases. Funnel plots of every comparison were symmetrical, which indicated that the combined results were unlikely to be seriously impacted by overt publication biases.

Discussion {#Sec14}
==========

The combined results of this meta-analysis revealed that *VDR* rs7975232, *VDR* rs2228570, *VEGF* rs699947, *VEGF* rs3025039, *IL-18* rs1946518, and *MBL* rs7096206 polymorphisms were significantly associated with susceptibility to HCC in certain populations. The trends of associations remained consistent in sensitivity analyses, which indicated that the combined results were statistically stable.

To better understand the combined results of this meta-analysis, some points should be considered. First, past basic studies revealed that all investigated polymorphisms were either correlated with altered transcription activity or protein structure \[[@CR45]--[@CR48]\]. So, these variations may influence the biological function of *VDR/VEGF/IL-18/MBL*, result in immune dysfunction, cause chronic inflammatory hepatocellular injury, and ultimately confer susceptibility to HCC. Thus, our meta-analysis may be statistically insufficient to observe the real underlying associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC in certain subgroups. Therefore, future studies still need to confirm our findings. Second, we noticed that most eligible studies were from Asian countries, whereas studies in other countries were highly scarce, so scholars from European and African countries should also try to examine associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC. Besides, considering the functional importance of VDR/VEGF/IL-18/MBL in regulating inflammatory reactions and angiogenesis, future studies also need to test the relationship between polymorphisms in *VDR/VEGF/IL-18/MBL* and other types of malignancies. Third, the ~~e~~tiology of HCC is very complicated, so we highly recommend further genetic association studies to explore the effects of haplotypes and gene-gene interactions on disease susceptibility \[[@CR49]\]. Fourth, we aimed to investigate associations between all polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC in the very beginning. However, we did not find any study on other *VDR/VEGF/IL-18/MBL* polymorphisms, so we only focused on 12 polymorphisms in this meta-analysis. Fifth, it is worth noting that Zhu et al. \[[@CR50]\] also performed a meta-analysis about *IL-18* polymorphisms and HCC in 2016. Based on combined analyses of eight eligible studies with 3572 subjects, they did not find any positive results regarding *IL-18* polymorphisms and HCC in general or subgroup analyses. Since our pooled analyses about *IL-18* polymorphisms were based on more eligible studies and larger sample sizes, our results should be more statistically robust. Nevertheless, studies with larger sample sizes are still warranted to test the genetic associations between *IL-18* polymorphisms and HCC in the future.

Some limitations of this meta-analysis should also be mentioned. Firstly, the results regarding associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC were based on combining unadjusted findings of eligible studies due to the lack of raw data \[[@CR51]\]. Secondly, the relationship between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC may also be affected by environmental factors. Unfortunately, the majority of eligible studies only focused on associations between polymorphisms in *VDR/VEGF/IL-18/MBL* and HCC, so we could not explore genetic-environmental interactions in this meta-analysis \[[@CR52]\]. Thirdly, grey literatures were not searched. So although funnel plots of every comparison were symmetrical, it is still possible that the combined results may be affected by publication biases \[[@CR53]\].

Conclusion {#Sec15}
==========

In summary, this meta-analysis proved that *VDR* rs7975232, *VDR* rs2228570, *VEGF* rs699947, *VEGF* rs3025039, *IL-18* rs1946518, and *MBL* rs7096206 polymorphisms may confer susceptibility to HCC in certain populations. These results also indicated that VDR, VEGF, IL-18, and MBL may involve in the development of HCC. However, the combined results of this meta-analysis should still be verified by studies with larger sample sizes.
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 {#Sec16}

**Additional file 1: Figure S1.** Forest plots of investigated polymorphisms.
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